Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to
Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).